Airis maintains long-standing tier-1 partnerships with Maithri Labs, Divi's Laboratories, and Laurus Labs — relationships that extend beyond off-the-shelf API supply into custom synthesis and DMF co-development. When a program demands a non-commodity API route, we work with our partners from impurity-profile design through DMF filing — ensuring API and formulation move in lockstep rather than sequentially.
Beyond development, Airis operates three formalized, audit-ready CMO partnerships — each chosen for distinct commercial-scale strengths. Together they span the full breadth of complex generic dosage forms: oral solids, oral liquids, sterile injectables, lyophilized products, oncology cytotoxics, softgels, and high-potent containment.
A partner who licenses an Airis dossier inherits not just the filing — but a pre-qualified, audit-ready manufacturing path from day one. No CMO-hunting, no tech-transfer guesswork, no scale-up risk transferred onto the licensor.
From custom API development through regulator-cleared dossier and into commercial manufacturing — every stage handled inside the Airis network. Partners who license our science inherit a complete, de-risked path to market.